Shots:
- China’s NMPA has approved Shingrix (Recombinant Zoster Vaccine) for the prevention of shingles (herpes zoster) in adults (≥18yrs.) at increased risk due to immunodeficiency or immunosuppression caused by known disease or therapy
- Approval was supported by 6 trials in pts (≥18yrs.) who had undergone recent stem cell transplantation, kidney transplant, or had blood cancer, solid tumor, or HIV
- Shingrix is a non-live recombinant subunit vaccine combining glycoprotein E with the AS01B adjuvant that is also approved to prevent shingles in adults (≥50yrs.) across multiple regions
Ref: GSK | Image: GSK | Press Release
Related News:- GSK Reports the US FDA’s sNDA Acceptance and Priority Review of Blujepa for Uncomplicated Urogenital Gonorrhoea
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
